Characterization of Reproductive, Metabolic, and Endocrine Features of Polycystic Ovary Syndrome in Female Hyperandrogenic Mouse Models

被引:249
|
作者
Caldwell, A. S. L. [1 ]
Middleton, L. J. [1 ]
Jimenez, M. [1 ]
Desai, R. [1 ]
McMahon, A. C. [2 ]
Allan, C. M. [1 ]
Handelsman, D. J. [1 ]
Walters, K. A. [1 ]
机构
[1] Univ Sydney, ANZAC Res Inst, Androl Lab, Sydney, NSW 2139, Australia
[2] Univ Sydney, ANZAC Res Inst, Biogerontol Lab, Sydney, NSW 2139, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会;
关键词
FOLLICLE-STIMULATING-HORMONE; PRENATAL TESTOSTERONE; ANDROGEN EXCESS; SYNDROME PCOS; TARGETED DISRUPTION; LUTEINIZING-HORMONE; RHESUS-MONKEYS; CYCLING RATS; MICE; DEHYDROEPIANDROSTERONE;
D O I
10.1210/en.2014-1196
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, causing a range of reproductive, metabolic and endocrine defects including anovulation, infertility, hyperandrogenism, obesity, hyperinsulinism, and an increased risk of type 2 diabetes and cardiovascular disease. Hyperandrogenism is the most consistent feature of PCOS, but its etiology remains unknown, and ethical and logistic constraints limit definitive experimentation in humans to determine mechanisms involved. In this study, we provide the first comprehensive characterization of reproductive, endocrine, and metabolic PCOS traits in 4 distinct murine models of hyperandrogenism, comprising prenatal dihydrotestosterone (DHT, potent nonaromatizable androgen) treatment during days 16-18 of gestation, or long-term treatment (90 days from 21 days of age) with DHT, dehydroepiandrosterone (DHEA), or letrozole (aromatase inhibitor). Prenatal DHT-treated mature mice exhibited irregular estrous cycles, oligo-ovulation, reduced preantral follicle health, hepatic steatosis, and adipocyte hypertrophy, but lacked overall changes in body-fat composition. Long-term DHT treatment induced polycystic ovaries displaying unhealthy antral follicles (degenerate oocyte and/or > 10% pyknotic granulosa cells), as well as anovulation and acyclicity in mature (16-week-old) females. Long-term DHT also increased body and fat pad weights and induced adipocyte hypertrophy and hypercholesterolemia. Long-term letrozole-treated mice exhibited absent or irregular cycles, oligo-ovulation, polycystic ovaries containing hemorrhagic cysts atypical of PCOS, and displayed no metabolic features of PCOS. Long-term dehydroepiandrosterone treatment produced no PCOS features in mature mice. Our findings reveal that long-term DHT treatment replicated a breadth of ovarian, endocrine, and metabolic features of human PCOS and provides the best mouse model for experimental studies of PCOS pathogenesis.
引用
收藏
页码:3146 / 3159
页数:14
相关论文
共 50 条
  • [31] Effects of Metformin on Endocrine and Metabolic Parameters in Patients with Polycystic Ovary Syndrome
    Zahra, M.
    Shah, M.
    Ali, A.
    Rahim, R.
    HORMONE AND METABOLIC RESEARCH, 2017, 49 (02) : 103 - 108
  • [32] A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice
    Kauffman, Alexander S.
    Thackray, Varykina G.
    Ryan, Genevieve E.
    Tolson, Kristen P.
    Glidewell-Kenney, Christine A.
    Semaan, Sheila J.
    Poling, Matthew C.
    Iwata, Nahoko
    Breen, Kellie M.
    Duleba, Antoni J.
    Stener-Victorin, Elisabet
    Shimasaki, Shunichi
    Webster, Nicholas J.
    Mellon, Pamela L.
    BIOLOGY OF REPRODUCTION, 2015, 93 (03)
  • [33] Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy
    Abbott, David H.
    Dumesic, Daniel A.
    Levine, Jon E.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2019, 14 (02) : 131 - 143
  • [34] Clinical, endocrine and ultrasonographic features of polycystic ovary syndrome in Thai women
    Vutyavanich, Teraporn
    Khaniyao, Vorathep
    Wongtra-Ngan, Supreeya
    Sreshthaputra, Opas
    Sreshthaputra, Rungaroon
    Piromlertamorn, Waraporn
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2007, 33 (05) : 677 - 680
  • [35] Metabolic and Reproductive Features Before and During Puberty in Daughters of Women With Polycystic Ovary Syndrome EDITORIAL COMMENT
    Sir-Petermann, Teresa
    Codnen, Ethel
    Perez, Virginia
    Echiburu, Barbara
    Maliqueo, Manuel
    Ladron de Guevara, Amanda
    Preisler, Jessica
    Crisosto, Nicolas
    Sanchez, Fernando
    Cassorla, Fernando
    Bhasin, Shalender
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2009, 64 (11) : 730 - +
  • [36] Progress of Adipokines in the Female Reproductive System: A Focus on Polycystic Ovary Syndrome
    Chen, Peipei
    Jia, Rui
    Liu, Yuanyuan
    Cao, Mingya
    Zhou, Liang
    Zhao, Zhiming
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [37] NORMOANDROGENIC VERSUS HYPERANDROGENIC WOMEN WITH POLYCYSTIC OVARY SYNDROME AND THEIR METABOLIC AND CARDIOVASCULAR PROFILE LATER IN LIFE.
    van der Ham, Kim
    Koster, Wendy
    Velthuis, Birgitta
    Budde, Ricardo
    Fauser, Bart
    Boersma, Eric
    Laven, Joop
    Louwers, Yvonne
    FERTILITY AND STERILITY, 2021, 116 (03) : E83 - E83
  • [38] Polycystic ovary syndrome and metabolic syndrome
    Auernhammer, CJ
    Engelhardt, D
    Parhofer, KG
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (18) : 971 - 977
  • [39] Metabolic syndrome and polycystic ovary syndrome
    Sobstyl, Malgorzata
    Tkaczuk-Wlach, Joanna
    Sobstyl, Jacek
    Jakiel, Grzegorz
    PRZEGLAD MENOPAUZALNY, 2011, 10 (01): : 74 - 78
  • [40] Polycystic ovary syndrome: a reproductive and metabolic web of risk, comorbidities, and disease
    Bates, G. Wright, Jr.
    FERTILITY AND STERILITY, 2019, 111 (03) : 471 - 472